Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
Systemic Piezo1 activation improves cerebrovascular function in Alzheimer's disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tabrizi Zeynab, Lim Xin Rui, Chakraborty Supriya, Harraz Osama F, Bracko Oliver
Аннотация
INTRODUCTION: Cerebral blood flow (CBF) reductions and impaired functional hyperemia (FH) are early features of Alzheimer's disease (AD) that contribute to disease progression. Here, we investigated whether systemic activation of the mechanosensitive ion channel Piezo1 affects cerebrovascular deficits in an AD mouse model.
METHODS: Using two-photon in vivo imaging and laser-speckle imaging, we determined CBF, capillary stalling, and FH in the 5xFAD model of AD.
RESULTS: We observed increased capillary stalling and reduced CBF and FH to whisker stimulation in 5xFAD mice compared to wild-type controls. The systemic administration of the Piezo1 agonist Yoda1 led to a ≈ 65% reduction in capillary stalls, increased CBF, and significantly improved FH in response to whisker stimulation, restoring CBF responses in 5xFAD mice to levels comparable to controls.
DISCUSSION: These results suggest that Piezo1 activation improves microvascular flow and neurovascular coupling in AD, highlighting Piezo1 as a promising therapeutic target for early cerebrovascular dysfunction during AD.
HIGHLIGHTS: An Alzheimer's disease (AD) animal model demonstrates reduced brain capillary blood flow and impaired neurovascular coupling. Pharmacological activation of Piezo1 at the systemic level improves blood flow and functional hyperemia during AD. Piezo1 is involved in cerebrovascular dysfunction associated with AD.
METHODS: Using two-photon in vivo imaging and laser-speckle imaging, we determined CBF, capillary stalling, and FH in the 5xFAD model of AD.
RESULTS: We observed increased capillary stalling and reduced CBF and FH to whisker stimulation in 5xFAD mice compared to wild-type controls. The systemic administration of the Piezo1 agonist Yoda1 led to a ≈ 65% reduction in capillary stalls, increased CBF, and significantly improved FH in response to whisker stimulation, restoring CBF responses in 5xFAD mice to levels comparable to controls.
DISCUSSION: These results suggest that Piezo1 activation improves microvascular flow and neurovascular coupling in AD, highlighting Piezo1 as a promising therapeutic target for early cerebrovascular dysfunction during AD.
HIGHLIGHTS: An Alzheimer's disease (AD) animal model demonstrates reduced brain capillary blood flow and impaired neurovascular coupling. Pharmacological activation of Piezo1 at the systemic level improves blood flow and functional hyperemia during AD. Piezo1 is involved in cerebrovascular dysfunction associated with AD.